{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T15:15:06Z","timestamp":1783350906768,"version":"3.54.6"},"reference-count":24,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T00:00:00Z","timestamp":1783123200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"This research received no external funding."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: HS is a chronic inflammatory skin disease in which inflammatory nodules and abscesses coexist with tunnels, fibrosis, and scarring. This dual biology explains why medical therapy often improves inflammatory dissease activity without fully addressing fixed tissue damage, whereas surgery can achieve durable local control but does not treat diffuse inflammatory burden. Contemporary international guidelines increasingly endorse multimodal and medicosurgical care. Objective: To critically compare the evidence supporting medical and surgical management of HS, with emphasis on outcomes, indications, limitations, and clinical decision-making relevant to contemporary practice. Methods: A structured review was undertaken using PubMed\/MEDLINE, the Cochrane Library, and major dermatology guideline sources, with searches updated to 7 May 2026. Priority was given to clinical guidelines, systematic reviews and meta-analyses, randomized controlled trials, and higher-quality observational studies. Evidence was synthesized narratively because endpoints, populations, and follow-up intervals differed markedly across medical and surgical studies. Results: Medical evidence is strongest for biologic therapy in moderate-to-severe inflammatory HS. Weekly adalimumab improved week-12 HiSCR in the phase 3 PIONEER trials; secukinumab improved week-16 and week-52 outcomes in SUNSHINE\/SUNRISE; and bimekizumab improved week-16 HiSCR50 in BE HEARD I\/II. Surgical evidence is strongest for wide excision in structurally advanced disease, particularly when compared with local excision or incision and drainage. Meta-analytic data consistently show lower recurrence after wide excision than after local excision, and lower recurrence after flap or graft reconstruction than after primary closure. Combined therapy is increasingly supported: peri-operative adalimumab improved outcomes in SHARPS, and surgery plus adalimumab outperformed adalimumab alone in a pragmatic 12-month RCT. Conclusions: HS is best managed by matching treatment to disease phenotype. Medical therapy is essential for inflammatory control; surgery is essential for persistent tunnels, fibrosis, and scarred regional disease. The strongest overall clinical position is an integrated, multidisciplinary model in which systemic therapy reduces inflammatory load and surgery definitively treats irreversible tissue damage.<\/jats:p>","DOI":"10.3390\/jcm15135238","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T13:43:14Z","timestamp":1783345394000},"page":"5238","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Medical and Surgical Management of Hidradenitis Suppurativa"],"prefix":"10.3390","volume":"15","author":[{"given":"John W.","family":"Frew","sequence":"first","affiliation":[{"name":"The Skin Hospital, 121 Crown St Darlinghurst, Sydney, NSW 2010, Australia"},{"name":"School of Clinical Medicine, University of New South Wales, Sydney, NSW 2060, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0418-521X","authenticated-orcid":false,"given":"Falk G.","family":"Bechara","sequence":"additional","affiliation":[{"name":"ICH\u2014International Center for Hidradenitis Suppurativa\/Acne Inversa, Department of Dermatology, Venereology and Allergology, Ruhr-University Bochum, 44801 Bochum, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1111\/bjd.17537","article-title":"British Association of Dermatologists guidelines for the management of hidradenitis suppurativa (acne inversa) 2018","volume":"180","author":"Ingram","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jaad.2019.02.067","article-title":"North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part I: Diagnosis, evaluation, and the use of complementary and procedural management","volume":"81","author":"Alikhan","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jaad.2019.02.068","article-title":"North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: Topical, intralesional, and systemic medical management","volume":"81","author":"Alikhan","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1111\/bjd.19710","article-title":"Guidelines for the management of hidradenitis suppurativa: Recommendations supported by the Centre of Evidence of the French Society of Dermatology","volume":"184","author":"Bertolotti","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/ajd.14388","article-title":"Australasian hidradenitis suppurativa management guidelines","volume":"66","author":"Frew","year":"2025","journal-title":"Australas. J. Dermatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/jdv.12966","article-title":"European S1 guideline for the treatment of hidradenitis suppurativa\/acne inversa","volume":"29","author":"Zouboulis","year":"2015","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1111\/jdv.20472","article-title":"European S2k guidelines for hidradenitis suppurativa\/acne inversa part 2: Treatment","volume":"39","author":"Zouboulis","year":"2025","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1159\/000503605","article-title":"A comparison of international management guidelines for hidradenitis suppurativa","volume":"237","author":"Hendricks","year":"2021","journal-title":"Dermatology"},{"key":"ref_9","first-page":"CD010081","article-title":"Interventions for hidradenitis suppurativa","volume":"2015","author":"Ingram","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1504370","article-title":"Two phase 3 trials of adalimumab for hidradenitis suppurativa","volume":"375","author":"Kimball","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S0140-6736(23)00022-3","article-title":"Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): Week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials","volume":"401","author":"Kimball","year":"2023","journal-title":"Lancet"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1016\/S0140-6736(24)00101-6","article-title":"Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): Two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials","volume":"403","author":"Kimball","year":"2024","journal-title":"Lancet"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/DSS.0000000000002892","article-title":"Current surgical management of hidradenitis suppurativa: A systematic review and meta-analysis","volume":"47","author":"Riddle","year":"2021","journal-title":"Dermatol. Surg."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/DSS.0000000000002403","article-title":"Recurrence rates following excision of hidradenitis suppurativa: A systematic review and meta-analysis","volume":"46","author":"Ovadja","year":"2020","journal-title":"Dermatol. Surg."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.1097\/DSS.0000000000002815","article-title":"Recurrence rates following reconstruction strategies after wide excision of hidradenitis suppurativa: A systematic review and meta-analysis","volume":"47","author":"Ovadja","year":"2021","journal-title":"Dermatol. Surg."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1111\/ijd.17553","article-title":"Wound closure techniques after wide excision for hidradenitis suppurativa: A systematic review and meta-analysis","volume":"64","author":"Cucu","year":"2025","journal-title":"Int. J. Dermatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/jdv.14770","article-title":"Hidradenitis suppurativa treated with wide excision and second intention healing: A meaningful local cure rate after 253 procedures","volume":"32","author":"Deckers","year":"2018","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1159\/000527400","article-title":"Patterns of surgical recurrence in patients with hidradenitis suppurativa","volume":"239","year":"2023","journal-title":"Dermatology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1007\/s13555-025-01623-8","article-title":"Defining surgical recurrence patterns in hidradenitis suppurativa: Insights from 206 procedures and literature review","volume":"16","year":"2026","journal-title":"Dermatol. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1001\/jamasurg.2021.3655","article-title":"Efficacy and safety of adalimumab in conjunction with surgery in moderate to severe hidradenitis suppurativa: The SHARPS randomized clinical trial","volume":"156","author":"Bechara","year":"2021","journal-title":"JAMA Surg."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.jaad.2023.04.034","article-title":"Adalimumab in conjunction with surgery compared with adalimumab monotherapy for hidradenitis suppurativa: A randomized controlled trial in a real-world setting","volume":"89","author":"Aarts","year":"2023","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"adv00257","DOI":"10.2340\/00015555-3616","article-title":"Neoadjuvant biologic therapy in the surgical management of patients with hidradenitis suppurativa: A cohort study","volume":"100","year":"2020","journal-title":"Acta Derm.-Venereol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1111\/ijd.17729","article-title":"Diagnostic Performance of GPT-4o and Gemini Flash 2.0 in Acne and Rosacea","volume":"64","author":"Boostani","year":"2025","journal-title":"Int. J. Dermatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e1052","DOI":"10.1111\/jdv.20861","article-title":"Large language models in evaluating hidradenitis suppurativa from clinical images","volume":"39","author":"Boostani","year":"2025","journal-title":"J. Eur. Acad. Dermatol. Venereol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/13\/5238\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T14:34:19Z","timestamp":1783348459000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/13\/5238"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,4]]},"references-count":24,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["jcm15135238"],"URL":"https:\/\/doi.org\/10.3390\/jcm15135238","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,4]]}}}